Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted options in conjunction with established multimodal treatment protocols for TGCT management. Upon completion of this activity, participants should be better able to: Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients where continued surgery is unlikely to produce clinical benefits; and Manage safety and dosing considerations with targeted agents in the setting of TGCT.